Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex versus neostigmine for reversal of rocuronium-induced neuromuscular blockade in cirrhotic patients undergoing liver resection
PACTR201411000912262Not yet recruiting
- Sponsor
- National Liver Institute
- Start
- Oct 2014
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Open-label trial of Sugammadex, neostigmine and rocuronium in Cirrhosis (4 arms), sponsored by National Liver Institute. Primary endpoint: Time to TOF ratio recovery to 0.9. Planned start Oct 2014; status: not yet recruiting.
02
Drugs
Sugammadexneostigminerocuronium
03
Conditions
Cirrhosis
Beyond the preview
Go deeper on PACTR201411000912262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201411000912262.